Reconstitution & dose calculator
When to stay put vs. adjust
Stay put at 250 IU 2× weekly for the first 4–6 weeks while baseline labs (testosterone, estradiol, LH if not on TRT) catch up. The endocrine response to hCG is gradual at the receptor level — the testicular response builds over weeks, not days. The dose is appropriate when testicular function (size, fertility markers if applicable) is preserved without significant estradiol elevation.
Consider stepping to 500 IU 2–3× weekly if testicular preservation isn't holding at the lower dose AND estradiol remains within range on labs. The 250–500 IU range is where most TRT-adjunct community evidence sits. Above 500 IU per injection, you're getting more aggressive about testicular stimulation and the estradiol-elevation question becomes more relevant.
Don't go above 1000–1500 IU per injection for TRT-adjunct use. Higher doses don't reliably produce proportionally better testicular preservation, and they drive estradiol elevation through testicular aromatization — you can end up needing an aromatase inhibitor to manage what the hCG is creating. Some PCT (post-cycle testosterone restart) protocols use higher doses, but that's a different context with different goals.
Estradiol monitoring matters more than testosterone monitoring on hCG. Testosterone responds gradually; estradiol can climb faster than expected because the testicles aromatize testosterone to estradiol locally. Symptoms of high estradiol (mood changes, water retention, gynecomastia onset) should prompt a lab check before dose escalation. This is the most common reason TRT-adjunct hCG goes off the rails.
Storage matters more than for most peptides. Once reconstituted, hCG is stable for ~30 days refrigerated, but the activity declines noticeably toward the end of that window. Don't reconstitute a vial you won't finish in a month. The 5,000 IU vial gives ~20 doses at 250 IU which is right at the edge of the 30-day window if dosing 2× weekly — the 10,000 IU vial is more vial than most TRT-adjunct users will use before stability declines.
Hard contraindications: hormonally-influenced cancers (prostate, breast), known precocious puberty, prior allergic reaction. Caution with cardiovascular disease, kidney/liver disease, asthma, epilepsy, migraine. The cancer contraindication is real because hCG drives androgen production via the testicular pathway.
The honest read. hCG used as a TRT adjunct is one of the better-grounded research-community uses on this site — it's an FDA-approved prescription drug being used in a way that's pharmacologically coherent with its mechanism (LH-receptor agonism preserving testicular function during exogenous testosterone use). The clinical evidence base is solid for the approved indications (fertility, hypogonadism); the TRT-adjunct use is off-label but well-characterized in clinical practice. The "hCG diet" weight-loss use, by contrast, is the bad version — multiple RCTs show no weight-loss effect beyond the very-low-calorie diet itself, and the FDA has issued specific warnings. Don't confuse the legitimate TRT-adjunct math above with that. If you're considering hCG, you should be working with a clinician who orders labs and adjusts based on what the labs show.
For educational and research purposes only. This is not medical advice. hCG is FDA-approved as a prescription medication for fertility, hypogonadism, and undescended testicles. Use as a TRT adjunct or for post-cycle testosterone restart is off-label and requires clinical supervision with regular estradiol and testosterone monitoring. Hormonally-influenced cancers (prostate, breast) are hard contraindications. Consult a licensed healthcare provider before any health decision.